Pacific Edge (ASX:PEB, NZE:PEB) noted that the "Genetic Testing in Oncology: Specific Tests" local coverage determination became effective on April 24 in the US, halting Medicare coverage of its Cxbladder tests, according to Monday's Australian and New Zealand bourse filings.
A Pennsylvania District Court Judge ruled that her court lacks the jurisdiction to hear the firm's claim against Medicare administrative contractor Novitas and the US Centers for Medicare and Medicaid Services.
Its advocacy efforts also did not yield a change to the effective date or retirement of the local coverage determination.
Pacific Edge currently generates around 60% of its US revenue from Medicare. It will not seek re-coverage of Cxbladder Detect as no new evidence has been published that can be submitted for reconsideration. Detect users will be required to move over to the Triage test.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。